The United States Centers for Disease Control and Prevention (CDC) advisory expert team voted on Thursday local time to recommend that Pfizer Inc/ BioNTech COVID-19 epidemic enhancement needles are provided to the elderly in the United States, nursing home residents and other vulnerable groups, clearing the way for the agency to make final approval at night at the earliest.

The agency's Advisory Committee on Immunization practice unanimously agreed to provide a third dose of Pfizer Inc COVID-19 vaccine to people aged 65 and above and residents of sanatoriums. The group also recommended intensive injections for adults between the ages of 18 and 64 with underlying diseases and rejected plans to provide a wide range of enhanced needles to the American public.

The US Food and Drug Administration (FDA) revised the emergency use authorization for Pfizer Inc and COVID-19 vaccine on the 22nd, allowing the elderly and high-risk groups to receive a booster dose of Pfizer Inc vaccine at least six months after the second dose of Pfizer Inc vaccine.